|Quantifying normal human brain metabolism using hyperpolarized [1–13C] pyruvate and magnetic resonance imaging|
JT Grist, MA McLean, F Riemer, RF Schulte, SS Deen, F Zaccagna, ...
Neuroimage 189, 171-179, 2019
|Imaging breast cancer using hyperpolarized carbon-13 MRI|
FA Gallagher, R Woitek, MA McLean, AB Gill, R Manzano Garcia, ...
Proceedings of the National Academy of Sciences 117 (4), 2092-2098, 2020
|CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response|
D Biasci, M Smoragiewicz, CM Connell, Z Wang, Y Gao, ...
Proceedings of the National Academy of Sciences 117 (46), 28960-28970, 2020
|Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study|
FM Walter, K Mills, SC Mendonça, GA Abel, B Basu, N Carroll, S Ballard, ...
The lancet Gastroenterology & hepatology 1 (4), 298-306, 2016
|Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer|
HM Kocher, B Basu, FEM Froeling, D Sarker, S Slater, D Carlin, ...
Nature communications 11 (1), 4841, 2020
|First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014|
B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ...
Clinical cancer research 21 (15), 3412-3419, 2015
|First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.|
JS De Bono, LA Mina, M Gonzalez, NJ Curtin, E Wang, JW Henshaw, ...
Journal of Clinical Oncology 31 (15_suppl), 2580-2580, 2013
|Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin|
B Basu, B Sirohi, P Corrie
Endocrine-Related Cancer 17 (1), R75-R90, 2010
|A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma|
N Cook, B Basu, DM Smith, A Gopinathan, J Evans, WP Steward, ...
British journal of cancer 118 (6), 793-801, 2018
|Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers|
TA Yap, R Kristeleit, V Michalarea, SJ Pettitt, JSJ Lim, S Carreira, D Roda, ...
Cancer discovery 10 (10), 1528-1543, 2020
|MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial|
D Sarker, R Plummer, T Meyer, MH Sodergren, B Basu, CE Chee, ...
Clinical cancer research 26 (15), 3936-3946, 2020
|Combining antiangiogenics to overcome resistance: rationale and clinical experience|
V Moreno Garcia, B Basu, LR Molife, SB Kaye
Clinical Cancer Research 18 (14), 3750-3761, 2012
|Targeting the DNA damage response in oncology: past, present and future perspectives|
B Basu, TA Yap, LR Molife, JS De Bono
Current opinion in oncology 24 (3), 316-324, 2012
|A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer|
AM Oza, UA Matulonis, A Alvarez Secord, J Nemunaitis, LD Roman, ...
Clinical Cancer Research 26 (5), 1009-1016, 2020
|Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial|
M Alunni-Fabbroni, K Rönsch, T Huber, CC Cyran, M Seidensticker, ...
Journal of Translational Medicine 17 (1), 1-15, 2019
|LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.|
C Gomez-Roca, E Yanez, SA Im, E Castanon Alvarez, H Senellart, ...
Journal of Clinical Oncology 39 (3_suppl), 94-94, 2021
|Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience|
E Ghorani, HH Wong, C Hewitt, J Calder, P Corrie, B Basu
Oncology 89 (5), 281-287, 2015
|PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer|
B Basu, SK Sandhu, JS De Bono
Drugs 72, 1579-1590, 2012
|A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.|
V Moreno Garcia, RD Baird, KJ Shah, B Basu, N Tunariu, M Blanco, ...
Journal of Clinical Oncology 29 (15_suppl), 3021-3021, 2011
|Assessing the impact of COVID-19 on liver cancer management (CERO-19)|
S Muñoz-Martínez, V Sapena, A Forner, JC Nault, G Sapisochin, ...
JHEP reports 3 (3), 100260, 2021